Optimizing pediatric dosing: a developmental pharmacologic approach.
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allPractical considerations for dose selection in pediatric patients to ensure target exposure requirements.Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407What is the right dose for children?Paediatric clinical pharmacology in the UK.Population pharmacokinetics of gentamicin and dosing optimization for infantsPaediatric models in motion: requirements for model-based decision support at the bedside.Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in IndiaPharmacokinetics of ethionamide in children.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsFactors affecting the development of adverse drug reactions (Review article)Knowledge-driven approaches for the guidance of first-in-children dosing.Antipsychotic drug toxicology in children.A review of the use of latanoprost for glaucoma since its launch.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.Population pharmacokinetic analysis during the first 2 years of life: an overview.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Considerations in the pharmacologic treatment and prevention of neonatal sepsis.Methods for pharmacokinetic analysis in young children.Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.A retrospective description of anesthetic medication dosing in overweight and obese children.Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model.Population pharmacokinetics of levetiracetam in neonates with seizures.Bridging Adult Experience to Pediatrics in Oncology Drug Development.Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study.
P2860
Q24609011-4F10457F-B219-4475-B281-5ED007C860D1Q27693518-754FF9F2-C2AC-459A-96D7-EB767A073490Q33559419-E6B97BCE-A8B6-4E35-83A5-BD22F37F0BB6Q34180493-D6C7DDD5-AA37-4B7D-9791-C449AD52534BQ34607600-0E007F97-159C-43A0-9213-02CD2113ECE3Q34923469-BB076053-6B53-41C4-9864-7E678D6ABC21Q34953686-EECB2C9B-90BA-43C2-829D-6A59DA6A0840Q35127567-BA649025-B790-4902-A864-DAA274047BE4Q35270526-69469B33-33C6-48D3-9E31-C20AED365F7BQ35898538-A4D64C6B-0055-46BE-938D-E332975BF578Q36501845-EDCF621E-F069-4F64-8F5C-6A6D31ADDE14Q37378093-F2A41E15-FE3C-420A-9319-54CCF7BE0387Q37631543-703ADF42-21E5-4DF0-819A-AA111A80CBDAQ37815555-00178384-E61F-4899-82FC-33C3D6CE577DQ37852719-DD71E4BD-BBD3-4253-BC61-7D0A931D397FQ37986149-2B33B176-CDE3-44B4-86D8-FB35B81E0059Q38026034-8C4A983F-328B-43E6-AE8F-1EE700F0FF73Q38062388-CF6E6FFD-A470-4217-B912-DDF380E0929FQ38152329-C72ED4E5-AB4C-46CE-BD75-4F9555C6DBD8Q38161849-BECB174B-5357-46EF-AA84-AA6E14B5F8C5Q38187157-C63B9D7B-1B5D-480D-9EE7-5CC16FCCCEDDQ38261290-95D8E06C-55E8-4CBB-925B-2C65FA6E825CQ38739169-FB63BB4E-D77A-4B71-B728-636BC6D3AEF4Q38748975-7459808C-F6CD-4522-A6AB-E8EA4838EFE9Q42720364-040A22A9-491F-49FD-8EA8-83C3C43126FFQ44781273-B75F45C3-1D3E-4658-8CB0-3452D16AE3F0Q47887588-24EA9BA8-CDDF-482B-B3D9-827CFD2670D8Q48277347-8B690B97-5516-4172-BA5F-F66676945518Q48371247-52885A95-E47A-4F00-913F-FF3E5D335F11Q50045460-278AF073-94E7-4686-BCE1-FB65FAC1793FQ55121600-C31D17DD-B51D-4CD8-9404-2CB754B640F6
P2860
Optimizing pediatric dosing: a developmental pharmacologic approach.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimizing pediatric dosing: a developmental pharmacologic approach.
@en
Optimizing pediatric dosing: a developmental pharmacologic approach.
@nl
type
label
Optimizing pediatric dosing: a developmental pharmacologic approach.
@en
Optimizing pediatric dosing: a developmental pharmacologic approach.
@nl
prefLabel
Optimizing pediatric dosing: a developmental pharmacologic approach.
@en
Optimizing pediatric dosing: a developmental pharmacologic approach.
@nl
P2860
P356
P1433
P1476
Optimizing pediatric dosing: a developmental pharmacologic approach.
@en
P2093
Anne M Lynn
Gail D Anderson
P2860
P304
P356
10.1592/PHCO.29.6.680
P407
P577
2009-06-01T00:00:00Z